Therapeutic | Figitumumab |
Target | IGF1R |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS |
Light Chain | DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-I |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | Pfizer |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Breast cancer, Colorectal cancer, Gastrointestinal cancer, Gynaecological cancer, Multiple myeloma, Non-small cell lung cancer, Prostate cancer, Rheumatoid arthritis, Sarcoma, Small cell lung cancer, Solid tumours |
Notes |